

CALL FOR ABSTRACTS

Submission Guidelines and Frequently Asked Questions

Abstract Submissions Open Thursday 9 April 2026

We are pleased to invite abstract submissions for oral presentations and scientific posters, at the [Luminesce Alliance 2026 Conference](#): *Partnerships in Action: Advancing Children's Health through Research, Families and Industry Collaboration* on 4 and 5 November 2026 at UNSW Sydney.

Abstracts from students and Early Career Researchers are strongly encouraged.

Submission Guidelines

Key Dates

Abstract Submissions Open	Thursday 9 April 2026
Abstract Submissions Close	Sunday 2 August 2026
Outcome Notification	Friday 11 September 2026
Presenters are required to register for Luminesce Alliance Conference 2026	Friday 2 October 2026

Presentation Types

There will be three presentation formats at the Luminesce Alliance 2026 Conference:

1. Concurrent Oral Presentation Session: oral presentation (10 minutes plus 5-minute question time)
2. Rapid Fire Oral Presentation: brief oral presentation (5 minutes)
3. Poster Presentation: hard copy posters will be on display with authors in attendance at a specified day/time to discuss their research with interested delegates.

You may nominate your preferred format. Please note as spaces for oral presentations are limited, abstracts not selected for oral presentations may be offered a rapid fire presentation or poster presentation. Speaker guidelines will be provided closer to the conference date.

Submission Guidelines

Submissions must be submitted by **Sunday 2 August 2026 midnight AEST** (Australian Eastern Standard Time).

To submit your abstract, click on the submit an abstract button below and follow the directions in the online abstract submission portal.

SUBMIT AN ABRRACT (BUTTON FORMAT)

Introduction

The Scientific Committee reserves the right to reject or return for re-submission with a strict deadline any abstract that does not comply with these guidelines.

Abstract Themes

- **For each abstract submitted** select **ONE OR TWO** of the Themes in the table below. The themes selected will assist in allocate talks to parallel sessions and posters to category areas.
- Based on your selections, the Scientific Committee assigns reviewers with the corresponding expertise to rate your abstract.

<input type="checkbox"/> Fundamental Biology & Mechanisms of Disease	Includes molecular pathways, gene regulation, developmental biology, functional genomics, CRISPR/High-Throughput Screening discovery, and disease modelling.
---	--

<input type="checkbox"/> Translational Science & Emerging Diagnostics	Biomarker discovery and validation, multi-omics integration, Variant of Uncertain Significance (VUS) resolution, advanced diagnostic technologies, and innovative non-animal models.
<input type="checkbox"/> Preclinical Therapeutics & Technology Platforms	Novel therapeutic targets, vectorology, gene and cell therapies, RNA-based treatments, paediatric pharmacology, and platform technologies enabling translation.
<input type="checkbox"/> Clinical Trials Innovation & Embedded Research Models	Adaptive/platform trials, early-phase paediatric trials, pragmatic and low-cost trial designs, and health-system-embedded research.
<input type="checkbox"/> AI, Digital Integration & Data-Driven Care	AI/machine learning in diagnostics and decision-support, EHR-omic integration, data standards, digital workflow adoption, and learning health systems.
<input type="checkbox"/> Equity, Access & Culturally Safe Paediatric Care	Research addressing inequities for Aboriginal and Torres Strait Islander, Culturally and Linguistically Diverse Community, Regional, rural and remote, and disability communities; culturally safe genomics; psychosocial models; and family-centred care.
<input type="checkbox"/> National Capability, Infrastructure & Workforce for Precision Medicine	Manufacturing and sovereign capability, med-tech and diagnostic scale-up, workforce development, and enabling infrastructure across discovery to care.
<input type="checkbox"/> Two-Way Learning Across Systems and Specialties	Cross-disciplinary insights from oncology and rare disease; models that enhance translation, scale, and health-system performance.
<input type="checkbox"/> Consumer & Community Partnership in Research	Co-designed research, consumer-led priority setting, participatory methodologies, lived experience as evidence, and community-based research translation.

Please prepare your abstract submission to include all the following sections, ready for uploading to the portal in the corresponding sections.

1. Title

- A brief descriptive title (maximum of 12 words) in Sentence case. Trademarks are not permitted.

2. Authors and Affiliations

- Institutional affiliations should include the city, state, and country. Each affiliation should be input in a separate section and will be allocated a superscript number.
- Authors' names and details, entered as instructed in the portal.
- Nominate the presenting author.

3. Abstract

- There is a maximum of 300 words allowed. The abstract text must not exceed 300 words, excluding the abstract title and author details.
- Text must be submitted as plain text without formatting. A limited number of symbols are available from the Special Character Keyboard.
- Tables, graphs, and charts are NOT permitted in abstracts.
- Abstracts should be carefully proofread and free of typographical and grammatical errors. The Scientific Committee reserves the right to correct abstracts for obvious spelling or grammatical errors without notice.
- Standard abbreviations may be used for common terms only. Otherwise, any abbreviation should be given in brackets after the first full use of the word.
- Abbreviations may be used in the title, provided the name in full is outlined in the body of the abstract.

Abstract sections

Abstracts should contain the following sections, each beginning a new paragraph:

- Background:** Aims and objectives of the study, what the study covers, relevant background information, and an outline of how the information will be presented.
- Methods:** Outline how the study was carried out and how the information was obtained.
- Results:** Present the results obtained from data gathering and the study. Results should be presented clearly, and concisely and record only the facts.
- Conclusion:** State or summarise the main points or findings of the study. This is where the aims of the study are revisited. No new information should be presented in this section.

Session Recording

Please note that by submitting your abstract and or agreeing to present, that you are consenting to your presentation being recorded for upload to <https://www.luminesce.org.au> and YouTube post the conference. If you do not wish your session to be recorded you can tick the opt out option during the submission process.

Abstract Review

All submitted abstracts will be reviewed by at least two reviewers. In evaluating each abstract, reviewers will be unaware of authors or institutions involved with the work described in the abstract. The following criteria will be used when assessing the abstract:

Reviewers will mark abstracts using the criteria provided below on a scale of 1 to 5 where 1=poor, 2= fair, 3=good, 4=very good, 5=excellent.

Criterion	Description	Guiding Questions	Score (1–5)	Weighting
A. Importance of the Topic	Assesses originality, relevance, and clarity of aims. Evaluates	Is the topic original, important, and relevant? Are the aims clearly described?	1–5	30%
B. Design and Methods	appropriateness and quality of study design and methodology. Reviews clarity and trustworthiness of findings or interim conclusions.	Is the design appropriate? Are methods clearly described? What is the overall quality? Are findings clearly described? How strong/trustworthy are the findings?	1–5	20%
C. Findings	Assesses the importance and potential impact of the work.	Includes interim assessments. How important are the findings? What is the likely influence on practice, education or policy?	1–5	20%
D. Implications (Significance)			1–5	30%

Abstracts on completed studies and research outcomes may be given preference in selecting the oral presentations, over abstracts that do not report results but indicate that they will be reported at the meeting or contain descriptions of trial methodology.

Notification of Outcome

Notification of outcome/acceptance will be emailed to the submitting author by **Friday 11 September 2026**.

It is the submitting author's responsibility to notify all other authors about the outcome of the reviewers' decision.

Oral Presentation and Poster Display

From the accepted abstracts, a selection will be scheduled for: the concurrent oral presentation session, rapid-fire oral presentation, and poster display.

For all accepted abstracts, further details regarding the oral presentation (PowerPoint presentation) and poster presentation (poster size, format, style and layout etc.) will be communicated to the submitting author.

Presenting Author Registration

If the presenting author cannot present at the time/date for the scheduled concurrent oral presentation session and the rapid-fire oral presentation an alternate can be considered. Alternate presenters need to be approved by the Scientific Committee.

No-Show Policy

Should a presenting author be absent without notice during the oral presentation sessions where the abstract is scheduled to be presented, the presentation will be cancelled.

Trademarks

Trademarks may be used in the abstract text but only in brackets and only once, i.e. the first time the product/service is mentioned. The identity of drugs/technologies described in the abstract should be disclosed using a generic name, a brief description or a reference to a public source.

Abstract Publication / Copyright

Submission of an abstract grants Luminesce Alliance permission to publish the abstract in the *Luminesce Alliance 2026 Conference* Online Program as well as the Luminesce Alliance website and monthly newsletter.

It is expected that the primary author/presenter will consult with co-authors/supervisors to provide consent for the abstract to be published. Abstract authors retain full copyright.

Contact

For questions or assistance with abstract submission please contact conference@aacb.asn.au

Eligibility criteria

- All abstracts must involve research related to one of the major themes listed under "Abstract theme".
- Abstracts must be submitted by the first or corresponding author and only 2 abstracts per first author can be submitted.
- An abstract must contain sufficient information so that, if published, it will be a complete report independent of presentation.
- The text should not contain statements alluding to results or conclusions not presented within the text.
- Abstracts pertaining to commercial promotion of a proprietary product will not be accepted.
- The Scientific Committee has the right of refusal to any abstract submitted at all times.
- All presenting authors (maximum of two) if selected by the Scientific Committee must register and pay to attend the Conference by **Friday 2 October 2026**. **Presenting authors will be offered the early bird registration price until Friday 2 October 2026**. If a nominated presenter is unable to present, any alternate presenters need to be approved by the Scientific Committee.
- For more detail refer to Frequently Asked Questions

Frequently Asked Questions (FAQs) and answers

What is an abstract?

An abstract is a concise, standalone statement briefly summarising the essential information of a study, encompassing its purpose, methods, results, and conclusions. A well-crafted abstract serves to showcase your project, contribute to practice or education, and foster connections with fellow researchers.

How many abstracts can I submit?

Each first author may submit up to two abstracts, but the same research cannot be submitted twice, even under a different topic/category or with a different title.

Can I submit an abstract by email?

No. Abstracts can be submitted only via the online abstract submission portal. Any abstract sent by email will not be accepted and automatically returned to the sender.

Who can submit an abstract?

Abstracts will only be accepted from the first author or a designated corresponding author of the submitted abstract who has registered and agrees to attend, upon selection, the *Luminesce Alliance 2026 Conference*. If you fail to register to attend the conference, the selected abstract will be withdrawn.

Who reviews the abstracts?

Submitted abstracts will be blind-reviewed and selected by the Scientific Committee.

How will your abstract be assessed?

The following criteria will be used when assessing the abstract:

A. Importance of the topic

- Is the topic original/important/relevant to conference themes?
- Are the aims of the study clearly described?

B. Design and methods

- Is the study design appropriate for the research aim(s), hypothesis(es) and question(s)?
- Are the methods clearly described?
- What is the overall quality of the study methods (utilised or proposed)?

C. Findings

- Are the key findings clearly described?
- How confident is the reviewer in the strength/trustworthiness of the findings and/or conclusions/discussion presented?

For work in progress, reviewers will assess the quality of the conclusions/discussion taking into account interim findings/conclusions.

D. Implications (significance)

- How important are the research findings?
- How and to what extent are the findings likely to influence clinical or research practice, education or policy?

The Scientific Review Committee will not accept abstracts about commercial promotion of a proprietary product.

How many words should my abstract contain?

There is a maximum of 300 words excluding tables and pictures. The 300-word limit excludes the title and authors.

Are tables and pictures permitted in the abstract submission?

No

Are there other general submission requirements?

Writing must be clear, concise, and grammatically correct. Abstracts and posters may not contain any type of advertising.

Can I submit an abstract that has been previously presented or published?

Only if there are considerable changes (e.g. new data). This needs to be validated by the author.

When will I hear whether my abstract was accepted or rejected?

Submitting authors will receive notification of the selection outcome via e-mail by **Friday 11 September 2026**.

Will all co-authors or third parties be notified?

No. Only the submitting author will be notified. It is up to the submitting author to notify the presenting author/co-authors.

If my abstract is accepted what happens?

You will receive notification regarding the acceptance of your abstract for one of the following presentation types at the Luminesce Alliance 2026 Conference:

- Concurrent Oral Presentation Session: oral presentation (10 minutes plus 5-minute question time)
- Rapid Fire Oral Presentation: 5-minute brief oral presentation
- Poster Presentation

If selected, you must register by Friday 2 October and pay for the conference by Friday 23 October to present

your work either face-to-face at an assigned time for oral presentations or to discuss your research during specific day/time slots for hard copy posters. This also applies to corresponding authors wishing to attend the conference. The registration fee is non-refundable in case of non-attendance.

Are all the authors eligible for a reduced registration rate?

There is no special registration rate for abstract authors. However early bird prices will be extended to allow abstract authors to access the early bird rates. Students are offered a reduced registration rate.

Can I change the assigned Presenter?

Yes, the presenting author can be changed by emailing conference@aacb.asn.au with the abstract title/paper number, advising the change. The presenter must be part of the submitted authors' list and be able to present and discuss all aspects of the research.

What if the assigned presenter cannot attend the oral presentations?

Should a presenting author be absent without notice during the oral presentation sessions where the abstract is scheduled to be presented, the presentation will be cancelled.

What do you mean by assigning and transferring rights and copyright to Luminesce Alliance?

The content belongs to the author(s) but if the abstract is accepted, the submitter agrees on behalf of all co-authors to give Luminesce Alliance the right to reproduce and distribute the work submitted.

I need to withdraw my abstract. How should I proceed?

The submitting author can withdraw by emailing conference@aacb.asn.au with the abstract title/paper number, with the subject line: 'Abstract withdrawal' advising that they wish to withdraw.

Where and when will my abstract be published?

All accepted abstracts will be available on the *Luminesce Alliance 2026 Conference* [website](#) from October to November 2026.

Where do I find the information on the presentation format for my oral and poster?

Detailed information related to your abstract presentation will be provided by email as part of your advice on the results of the selection process.

Who is my audience?

Meeting delegates include scientists, clinicians, researchers, trainees, government, and other health representatives.

Can I change/edit my abstract?

Prior to the abstract submission deadline (Sunday 2 August 2026), you can edit your abstract directly in the abstract submission portal if it is saved as a draft. Any changes to a submitted abstract must be emailed to conference@aacb.asn.au prior to the abstract submission deadline, as you cannot edit directly in the portal once the abstract is submitted.